Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company's products are sold in countries around the world. Eli Lilly's products include neuroscience products, endocrine products, anti-infectives, cardiovascular agents, oncology products, and animal health products.

The company is correctly valued with a price earnings ratio of 12x, against average sector of 16x. According to Surperformance trading ratings, the group has strong fundamentals, both in terms of business predictability and valuation.

Following a bullish wave, the stock now shows a slight decline that should lead towards its USD 41.47 medium-term support. On this level, remobilization of buyer flows would allow an uptrend in the medium and long term. Investors could take a buy order on this level and get a good entry point with a first target price of USD 44.5 and a stop below the medium term support.